George Yancopoulos - President and Chief Scientific, Regeneron Pharmaceuticals, Inc
As of December 23, 2021
What is George Yancopoulos's Net Worth?
The current estimated net worth of Regeneron Pharmaceuticals, Inc's President and Chief Scientific, George Yancopoulos, is estimated to be about $644.4M . George Yancopoulos owns about 1,101,176 units of Regeneron Pharmaceuticals, Inc common stock. In the last 18 years at Regeneron Pharmaceuticals, Inc, George Yancopoulos has sold an estimated value of $1.16B worth.
What is George Yancopoulos's Past Insider Trading?
George Yancopoulos's largest purchase order was 246,736 units , worth over $7.56M on March 11, 2020. George Yancopoulos's largest sale order was 246,736 units , worth over $116.85M on March 11, 2020. In total, George Yancopoulos has made about 54 transactions over 18 years of their time at Regeneron Pharmaceuticals, Inc. George Yancopoulos usually trades in December, with the busiest year in 2012. The most recent transaction was a sale order of 50,000 units , worth over $31.26M on August 17, 2021.
George Yancopoulos
Ticker
|
Type
|
Value
|
Price per Share
|
Shares
|
Filing Date
| ||
|---|---|---|---|---|---|---|---|
| No matching records found | |||||||
What was George Yancopoulos's Salary in 2020?
As President and Chief Scientific of Regeneron Pharmaceuticals, Inc, George Yancopoulos has a total base salary of $1,258,096 . George Yancopoulos received compensation valued at about $134,383,319 in 2020 after becoming President and Chief Scientific. The vast majority of their compensation came in the form of stock awards of $130,000,032 , other earnings, plans or compensations of $3,004,391 , other earnings, plans or compensations of $3,004,391 , and other compensation of $120,800 .
Regeneron Pharmaceuticals, Inc Executive Compensation
Name |
Year
|
Salary
|
Stock Awards
|
Other Earnings Plans or Compensations
|
Other Earnings Plans or Compensations
|
Other Compensation
|
Total
|
|---|---|---|---|---|---|---|---|
| Leonard S. Schleifer, M.D., Ph.D. | 2020 | $1,480,119 | $130,000,032 | $3,567,714 | $3,567,714 | $302,256 | $135,350,121 |
| Leonard S. Schleifer, M.D., Ph.D. | 2019 | $1,377,100 | $4,983,226 | $3,057,162 | $3,057,162 | $338,043 | $21,455,117 |
| Leonard S. Schleifer, M.D., Ph.D. | 2018 | $1,330,500 | - | $2,953,710 | $2,953,710 | $896,432 | $26,520,555 |
| George D. Yancopoulos, M.D., Ph.D. | 2020 | $1,258,096 | $130,000,032 | $3,004,391 | $3,004,391 | $120,800 | $134,383,319 |
| George D. Yancopoulos, M.D., Ph.D. | 2019 | $1,170,500 | $4,983,226 | $2,598,510 | $2,598,510 | $212,313 | $20,664,135 |
| George D. Yancopoulos, M.D., Ph.D. | 2018 | $1,130,900 | - | $2,510,598 | $2,510,598 | $399,718 | $25,381,129 |
| Robert E. Landry | 2020 | $825,577 | $949,560 | $938,872 | $938,872 | $24,195 | $6,197,703 |
| Robert E. Landry | 2019 | $730,000 | $2,840,008 | $811,395 | $811,395 | $23,470 | $7,931,542 |
| Robert E. Landry | 2018 | $680,000 | $4,767,500 | $581,400 | $581,400 | $19,535 | $9,356,619 |
| Daniel P. Van Plew | 2020 | $825,577 | $3,409,560 | $938,872 | $938,872 | $20,945 | $8,654,453 |
| Daniel P. Van Plew | 2019 | $683,100 | $2,840,008 | $759,266 | $759,266 | $20,470 | $7,829,513 |
| Daniel P. Van Plew | 2018 | $660,000 | - | $677,160 | $677,160 | $19,915 | $9,007,222 |
| Andrew J. Murphy, Ph.D. | 2020 | $726,923 | $5,025,288 | $887,250 | $887,250 | $24,195 | $10,998,914 |
| Andrew J. Murphy, Ph.D. | 2019 | $600,000 | $4,702,308 | $666,900 | $666,900 | $23,470 | $9,519,347 |
| No matching records found | |||||||
Source: https://www.sec.gov/Archives/edgar/data/872589/000093041321000869/c101011_def14a.htm
What are Regeneron Pharmaceuticals, Inc's Past Insider Trades?
Regeneron Pharmaceuticals, Inc's most recent insider trade came on June 3, 2022 by Marion McCourt who sold 1,100 units worth $736.46K . In the last 19 years, insiders at Regeneron Pharmaceuticals, Inc have sold an estimated value of $17.26B and bought an estimated value of $3.4B worth of shares. Insider trading is most common in December, with the busiest year in 2014. The most active traders at the company are Joseph L Goldstein, Director, Michael S Brown, Director, and P. Roy Vagelos, Director .
REGENERON PHARMACEUTICALS, INC. Insider Trades
Insider Names
|
Type
|
Value
|
Price per Share
|
Shares
|
Filing Date
| ||
|---|---|---|---|---|---|---|---|
| No matching records found | |||||||